Last reviewed · How we verify
Huaiqihuang granules
At a glance
| Generic name | Huaiqihuang granules |
|---|---|
| Also known as | B12000050755 |
| Sponsor | The First Affiliated Hospital of Dalian Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 (PHASE4)
- The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children (PHASE4)
- The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (PHASE4)
- The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
- Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Huaiqihuang granules CI brief — competitive landscape report
- Huaiqihuang granules updates RSS · CI watch RSS
- The First Affiliated Hospital of Dalian Medical University portfolio CI